Melane Sampson, Author at BioTuesdays

Developments

Capricor reveals positive data from HOPE-2 trial of deramiocel in DMD

Capricor Therapeutics (NASDAQ:CAPR) announced positive long-term data from its on-going HOPE-2 trial demonstrating the potential of its lead candidate, deramiocel, to slow disease progression and preserve upper limb...

March 17, 2025

Developments

Perimeter reaches regulatory milestone with FDA PMA submission for next-gen B-Series OCT with ImgAssist AI 2.0

Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) announced that it has filed a premarket approval (PMA) application for its next-generation B-Series OCT system, which combines proprietary AI technology with optical...

March 17, 2025

Developments

Biovica partners with Outcomes4Me to support HR-positive mBC patients

Biovica International (STO:BIOVIC-B; FRA:911) announced that it has partnered with Outcomes4Me to support post-menopausal patients with hormone (HR)-positive metastatic breast cancer (mBC) in understanding treatment...

March 12, 2025

Executive Moves

Matinas names Keith Murphy and Edward Neugeboren to BOD

Matinas BioPharma (NYSE American:MTNB) has appointed biotech industry veterans Keith Murphy and Edward Neugeboren to its board of directors (BOD) as independent members, effective today. Also effective today, Matinas...

March 11, 2025

Developments

Trevi reports positive Phase 2a trial data of Haduvio for RCC

Trevi Therapeutics (NASDAQ:TRVI) announced positive topline results from its Phase 2a RIVER study of oral nalbuphine ER (Haduvio) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF)...

March 10, 2025

Developments

PDS launches Phase 3 trial for HNSCC

PDS Biotechnology (NASDAQ:PDSB) announced that it has commenced its Phase 3 trial, VERSATILE-003, to evaluate the efficacy and safety of Versamune HPV plus pembrolizumab for head and neck squamous cell carcinoma (HNSCC)...

March 10, 2025

Developments

Oragenics submits IB for Phase 2 trial of ONP-002 in mTBI

Oragenics (NYSE American:OGEN) announced the submission of an Investigator Brochure (IB) in preparation for its Phase 2 trial evaluating ONP-002 for mild traumatic brain injury (mTBI), commonly known as concussion...

March 6, 2025

Developments

SIR accepts Autonomix abstract showcasing study results

Autonomix Medical (NASDAQ:AMIX) announced that the Society of Interventional Radiology (SIR) has accepted its abstract highlighting its technology and early proof-of-concept study results for a poster presentation at...

March 6, 2025

Developments

EPO to grant Moleculin’s Annamycin new patent allowances strengthening global exclusivity

Moleculin Biotech (NASDAQ:MBRX) announced that it received a Notice of Intent to Grant from the European Patent Office (EPO) for its patent application covering Annamycin, a potential next-generation, non-cardiotoxic...

March 6, 2025

Developments

Arch announces non-brokered private placement

Arch BioPartners (TXSV:ARCH; QTCQB:ACHFF) has arranged a non-brokered private placement of 225,806 common shares at $1.55 per share, generating proceeds of CAD $350,000. According to Arch, the offering, set to close...

March 5, 2025

Author - Melane Sampson

Capricor reveals positive data from HOPE-2 trial of deramiocel in DMD

Perimeter reaches regulatory milestone with FDA PMA submission for next-gen B-Series OCT with ImgAssist AI 2.0

Biovica partners with Outcomes4Me to support HR-positive mBC patients

Matinas names Keith Murphy and Edward Neugeboren to BOD

Trevi reports positive Phase 2a trial data of Haduvio for RCC

PDS launches Phase 3 trial for HNSCC

Oragenics submits IB for Phase 2 trial of ONP-002 in mTBI

SIR accepts Autonomix abstract showcasing study results

EPO to grant Moleculin’s Annamycin new patent allowances strengthening global exclusivity

Arch announces non-brokered private placement

Subscribe